Diamond Biofund Announces Changes in Investment Holdings, Fair Value, Net Asset Value Per Share, and Cash Balance
鑽石生技投資公告115年3月份投資標的股數與公允價值變動，以及每股淨值與現金餘額。
📋 Article Processing Timeline
- 📰 Published: April 9, 2026 at 09:00
- 🔍 Collected: April 10, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 17, 2026 at 01:06 (881h 6m after Collected)
Diamond Biofund Inc. announced its monthly report for March. The holdings of most invested companies remained unchanged, but the total fair value decreased by NT$84,898 thousand due to stock price fluctuations, with StemCyte and Sinphar suffering the most significant drops. As of the end of March, the net asset value per share was NT$10.40, and the cash and cash equivalents balance stood at NT$2,733,439 thousand. The company noted that investments in biotech stocks are highly volatile due to R&D outcomes, which may result in negative operating revenue when fair value declines.